In our study, among the 90 mucinous adenocarcinoma cases, the deletion ratios of SMARCA4, SMARCA2, and ARID1A subunits were 6.7%, 5.6%, and 4.5%, respectively. This evidence concerns the gene SMARCA2 and mucinous adenocarcinoma.